No. I think an approvable letter is more likely. I don't think the FDA will be comfortable with laropiprant safety yet (there are no long-term usage data for it).
BTW, after looking here the data we're discussing were pulled from these 4 trials started on Jun. 2007:
I think that the Niaspan used in the trial was not the more recently introduced version (lower flushing incidence) so another point that can narrow the difference.
Market Data 
Markets 
AI
